Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Ibrutinib | ENANTA PHARMACEUTICALS INC (ENTA) |
Frequently asked questions
How many drugs are in development for Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma?
BioSniper tracks 1 drug in development for Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma across 1 company.
How many clinical trials target Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma?
There are 1 clinical trial targeting Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma tracked by BioSniper.
What is the prevalence of Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma?
The estimated prevalence of Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis